

## ASX Announcement

# BCAL Diagnostics Launches BREASTEST *plus*<sup>™</sup> - Generating First Revenues

### Highlights:

- **BREASTEST *plus*<sup>™</sup> and first sales revenue this week**
- **Additional patents granted**

**Sydney, Australia – 24 March 2025** – BCAL Diagnostics Limited (ASX: BDX) (BCAL or the Company), an Australian and US-based biotechnology company pioneering non-invasive breast cancer diagnostics, is pleased to announce the commercial launch of BREASTEST *plus*<sup>™</sup>. This first-in-class blood test is available from Thursday, 27 March 2025 and will be used alongside standard-of-care imaging in breast cancer screening and diagnostics. The Company is pleased that this launch has been achieved within the previously announced target timeframe of having the test commercially available in Australia by the end of 1Q CY2025.

BREASTEST *plus*<sup>™</sup> has been validated to meet the challenge of high breast density, which affects approximately 50% of Australian women participating in breast cancer screening programs. High breast density masks abnormal lesions on mammography, in many cases making it difficult to diagnose. In line with the Company's stated market entry strategy, BREASTEST *plus*<sup>™</sup> will provide clinicians with a new, additional tool to help overcome this longstanding challenge.

### Marking a New Era in Breast Cancer Diagnostics with Focused Launch

BREASTEST *plus*<sup>™</sup> will be available at Sydney Breast Clinic from Thursday this week, with a planned roll out to additional select clinical sites, initially in Sydney and Melbourne, to follow. BCAL is focused on ensuring a systematic national rollout, working closely with our clinical partners, to ensure Australian women will have access to BREASTEST *plus*<sup>™</sup>.

BCAL collaborated with its Clinical Advisory Board of eminent Australian breast surgeons, radiologists and physicians to develop BREASTEST *plus*<sup>™</sup>, ensuring it meets the needs of women with high breast density who are often the most challenging to diagnose via traditional imaging.

**Chief Executive Officer, Shane Ryan commented:** "The commercial launch of BREASTEST *plus*<sup>™</sup> is an incredible milestone for BCAL and for the future of breast cancer screening. This innovative blood test has the potential to significantly improve the early detection pathway of breast cancer, and places BCAL at the forefront of blood-based tests for the detection of breast cancer.

We look forward to rolling out BREASTEST *plus*<sup>™</sup> nationally and ensuring widespread adoption and long-term success, supporting women and clinicians with cutting-edge screening tools."

**Breast Surgeon and Head of BCAL's Clinic Advisory Board, Dr David Speakman commented:** "Anything we can do to detect breast cancer earlier, to rule it in or out, is a vital step forward for women and saving more lives.

"This simple blood test can aid clinicians and their patients, in assessing for any sign of breast cancer which is a step change from relying on breast imaging alone."

## Intellectual Property (IP) Protection Update

BCAL's innovative approach to breast cancer diagnostics is further reinforced by the granting of its first self-developed patent, Diagnostic Signature (Australian Patent No. 2023258393), by IP Australia. This patent secures key methods and lipid markers integral to the BREASTEST *plus*™ technology, providing intellectual property protection through to 2043.

Additionally, BCAL has the exclusive global rights to intellectual property related to the application of lipidomic information in the diagnosis of cancers from the University of Louisville (USA).

This announcement has been approved for release by the Board of BCAL Diagnostics Limited.

## ENDS

### For further information:

**Jayne Shaw**

Executive Chair

Jshaw@bcaldiagnostics.com

**Shane Ryan**

Chief Executive Officer

Sryan@bcaldiagnostics.com

**Investor & Media Enquiries**

Tanya Thomas

Director Investor Relations &  
Communications

Tthomas@bcaldiagnostics.com

### About BREASTEST *plus*™

BREASTEST *plus*™ is the first product in BCAL's BREASTEST® range of non-invasive, lipid-based breast cancer diagnostics. BREASTEST *plus*™ is a first in class blood test that measures a panel of lipids, using Liquid Chromatography Mass Spectrometry, to identify a lipidomic breast cancer signature. BREASTEST *plus*™ is a 'rule-out' test that has been designed to be used in women with dense breasts and alongside mammography to improve screening and diagnostic outcomes for women.

### About BCAL Diagnostics

BCAL Diagnostics is an Australian and US-based biotechnology company dedicated to advancing early and accurate breast cancer detection. Our innovative, non-invasive blood test, the first in the BREASTEST® range of products is designed to complement existing breast screening methods and provide additional lipidomic insights to rule-out breast cancer, empowering women and their clinicians with greater confidence in diagnostic outcomes. Improved screening accuracy potentially reduces unnecessary follow-ups and enables timely intervention resulting in better health outcomes for women.

Founded in 2010, BCAL is headquartered in Sydney, AUS and listed on the Australian Securities Exchange (ASX: BDX). For more information: <https://www.bcaldiagnostics.com/> or contact [info@bcaldiagnostics.com](mailto:info@bcaldiagnostics.com).